Tumor and Metastasis Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
J Clin Invest. 2010 Aug;120(8):2979-88. doi: 10.1172/JCI40252. Epub 2010 Jul 19.
Pulmonary metastasis remains the leading ca use of death for cancer patients. Opportunities to improve treatment outcomes for patients require new methods to study and view the biology of metastatic progression. Here, we describe an ex vivo pulmonary metastasis assay (PuMA) in which the metastatic progression of GFP-expressing cancer cells, from a single cell to the formation of multicellular colonies, in the mouse lung microenvironment was assessed in real time for up to 21 days. The biological validity of this assay was confirmed by its prediction of the in vivo behavior of a variety of high- and low-metastatic human and mouse cancer cell lines and the discrimination of tumor microenvironments in the lung that were most permissive to metastasis. Using this approach, we provide what we believe to be new insights into the importance of tumor cell interactions with the stromal components of the lung microenvironment. Finally, the translational utility of this assay was demonstrated through its use in the evaluation of therapeutics at discrete time points during metastatic progression. We believe that this assay system is uniquely capable of advancing our understanding of both metastasis biology and therapeutic strategies.
肺转移仍然是癌症患者死亡的主要原因。为了提高患者的治疗效果,需要新的方法来研究和观察转移进展的生物学特性。在这里,我们描述了一种体外肺转移测定法(PuMA),该方法可以实时评估表达 GFP 的癌细胞从单个细胞到多细胞集落形成在小鼠肺部微环境中的转移进展,最长可达 21 天。该测定法的生物学有效性通过其对多种高转移和低转移的人类和小鼠癌细胞系的体内行为的预测,以及对肺部最有利于转移的肿瘤微环境的区分得到了证实。使用这种方法,我们提供了对肿瘤细胞与肺部微环境基质成分相互作用的重要性的新见解。最后,通过在转移进展的离散时间点评估治疗药物,证明了该测定法的转化实用性。我们相信,该测定系统能够独特地提高我们对转移生物学和治疗策略的理解。